News and Announcements
Advanced Materials Provider Disrupting the Aerospace Industry
- Published December 11, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Alvant is a leader in the design and manufacture of Aluminium Matrix Composite (AMC) materials.
With the potential to be utilised across a range of industries, AMCs not only help meet sustainability targets but also substantially enhance product capability.
AMCs offer the stiffness and strength of steel combined with the weight of aluminium.
£11m invested to date in product development.
Alvant is excited about the future and the impact its material solutions can have in helping customers produce sustainable yet highly capable products.
Alvant Investment Highlights
Problem
There is increasing pressure on manufacturers and OEM’s, from both government policy and customer demand, to improve the sustainability of their products while also meeting stringent cost and performance requirements. Alvant’s material technology is perfectly aligned to combat this global issue due to their ability to substantially reduce component mass, increase product capability and extend life.
Key Market
Aerospace is a strong focus area for Alvant as it is one of the industry sectors under the most pressure to mitigate its greenhouse gas emissions. According to the European Commission, direct emissions from aviation account for about 3% of the EU’s total greenhouse gas emissions and more than 2% of global emissions. Alvant has embarked on a number of projects with large aerospace OEMs including working on the design of aircraft landing gears of the future.
Value Proposition
- Value proposition based on a combination of lower raw material costs, reduced opex and lower maintenance/repair costs.Aircraft landing gear made using AMCs can have ~80% lower raw material costs
- Lower weight yields several £millions in annual fuel cost savings
- Longer component fatigue life reduces the need for maintenance, delivering additional £millions in cost savings across an airline fleet
Patent & Technology
Advanced Liquid Pressure Forming process.
- Original UK patent (2004)
- European patent granted (2008)
- Japanese patent granted (2009)
- US patent granted (2014)
Revenue Model
Business model is based on three main activities:
- Engineering services
- Manufacturing
- Licensing
Team
- New management team structure
- Board re-structure in 2018 and new Non Executive Chairman appointed in December 2019 leading a transition from technology development to commercial sales
- Commercial experience is drawn from aerospace, automotive and high-tech engineering
Performance
£1.1m revenue in FY2018/19 from commercial sales and development projects.
Targeting £20m revenue and £8.6m EBITDA within 5 years.
Competitive Advantage
Strong competitive position.
- Patented manufacturing process and proprietary materials
- Limited competition
Not only does Alvant own the proprietary rights to the ALPF AMC manufacturing process, it also provides clients with an end-to-end solution, offering engineering consultancy, concept development and component design through to prototype manufacture, low volume production, and the sale of licensing for higher volume production.
Milestones
- The transition from Composite Metal Technology to ALVANT, the new team, new structure, new business model and a commercial focus.
- Winning commercial business with our global Aerospace & Automotive clients
Investment Offering
Having raised £2.3m in the current funding round (£3.0m) Alvant is looking to close early in 2020.
The next stage of funding will be provided through a market relevant strategic partner where conversations are already underway.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
